Comparer des méthodes
Examinez les méthodes sélectionnées côte à côte ; les lignes qui diffèrent sont mises en évidence.
| Facteur de similarité f1/f2 pour la dissolution× | Administration de médicaments par voie liposomale× | |
|---|---|---|
| Domaine | Pharmacologie | Pharmacologie |
| Famille | Process / pipeline | Process / pipeline |
| Année d'origine≠ | 1996 | 1965 |
| Auteur d'origine≠ | James Moore and Hector Flanner | Alec Bangham |
| Type≠ | similarity testing | formulation technology |
| Source fondatrice≠ | Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74. link ↗ | Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252. DOI ↗ |
| Alias | f1, f2, similarity factor | liposomal formulation, vesicular delivery, lipid nanoparticles |
| Apparentées | 3 | 3 |
| Résumé≠ | The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release. | Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market. |
| ScholarGateJeu de données ↗ |
|
|